Workflow
Finbold
icon
搜索文档
Jim Cramer threatens to ‘expose' those ‘lying about Nvidia'
Finbold· 2025-04-01 22:16
The 2025 stock market downturn appears to have gotten to the legendary yet frequently mocked Mad Money host Jim Cramer. Indeed, the popular TV personality has started to defend his favored stock picks with relentless vigor in his X post, with a prime target of his ire being directed toward Nvidia (NASDAQ: NVDA) bears. At the tail end of a five-part tweet series published on April 1, Cramer warned that many are lying about NVDA and that he would, unless they stop, 'expose them.' The death cross has already o ...
Analyst sets Lucid stock price target
Finbold· 2025-04-01 17:52
Despite its optimistic promises from the initial public offering (IPO) era, the electric vehicle (EV) maker Lucid (NASDAQ: LCID) hasn't been known as a stellar stock market performer. LCID shares are more than 75% below their first-day value of $9.89, have lost 15.38% of their value in the last 12 months, and crashed 20% in 2025 despite the strong February rally on a set of positive developments, including a better-than-expected fourth-quarter (Q4) delivery report, and a surprise $5 price target with a 'buy ...
Michael Burry's biggest stock holding is on fire — and Wall Street is taking notice
Finbold· 2025-04-01 16:31
Michael Burry's biggest claim to fame might be his handling of the 2008 financial crisis, illustrated in 'The Big Short', but the savvy investor is still quite active in the financial markets. After an unsuccessful attempt to short the semiconductor industry, Burry made yet another controversial, heterodox decision. He ditched U.S. equities — and focused on the (at the time) relatively undervalued Chinese market. This time around, Michael Burry seems to have gotten it right yet again. While the S&P 500 has ...
$1.6 trillion asset manager just announced stake in this Michael Burry stock pick
Finbold· 2025-03-31 22:01
文章核心观点 - 美国银行因京东增长潜力宣布入股,华尔街因京东出色财报对其股票转为看涨 [1][7] 美国银行入股京东 - 资产规模达1.6万亿美元的美国银行宣布入股中国电商巨头京东,购入1%股份 [1][3] - 入股原因包括京东在电商领域的领先地位、直销与第三方商家平台的双业务模式、对物流基础设施的重大投资,以及有望高于行业平均增长并受益于政府刺激政策 [3][4] - 1%的股份体现了对京东前景的谨慎信心,投资兼顾了风险回报限制 [5] 京东股价表现 - 2025年美国股市大幅波动,京东作为中概股表现突出,年初至今涨幅超20%,截至发稿时估值为40.91美元 [2] 华尔街对京东股票的看法 - 京东公布出色季度财报后,多数华尔街机构对其股票转为看涨,该季度营收475亿美元,同比增长13.4% [7] - 3月12日,Susquehanna将京东目标价从35美元上调至45美元,维持“中性”评级,看好其2025年前景 [8] - 3月10日,花旗分析师Alicia Yap将京东目标价从51美元上调至56美元,重申“买入”评级,预计营收和非GAAP净利润同比增长11% [9] - 3月7日,瑞穗证券将京东目标价从43美元上调至50美元,维持“跑赢大盘”评级,提及营收加速和利润率扩张 [10]
Over 1,000 stocks are paying dividends today; Here's the stand-out name
Finbold· 2025-03-31 20:00
文章核心观点 2025年第一季度末超1000只证券将支付股息,在美股下跌背景下派息股票可缓冲波动,半导体巨头博通是突出的股息股票,虽股价下跌但有增长潜力,华尔街大多看好其股票 [1][2][5] 股息支付情况 - 2025年第一季度末超1000只包括股票和ETF的证券于3月31日支付股息,在美股过去三个月下跌背景下,派息股票可缓冲波动 [1] - 博通今日股息维持每股0.59美元不变,派息率30.14%,有15年股息增长记录,收益率1.25% [3] 第一季度业绩情况 - 博通2025年第一季度调整后每股收益1.60美元,超1.49美元的预期,营收达149.2亿美元,超146.1亿美元的预测 [3] - 该季度公司人工智能收入同比增长77%至41亿美元,基础设施软件部门受收购威睿推动,营收达67亿美元,同比增长47% [4] 股价现状与前景 - 博通股价年初至今下跌27%,上一交易日收盘价为169美元,但基于关键基本面仍有增长潜力 [5] - 其增长前景核心是对人工智能专用集成电路的强劲需求,主要客户如谷歌和Meta用其训练生成式人工智能模型 [6] - 博通推出行业首个面对面3.5D XPU,信号密度提高七倍,功率效率比以前设计高10倍 [6] - 公司处于下一代芯片开发前沿,3纳米XPU将于2025年末量产,2纳米人工智能XPU也在规划中 [7] - 博通预计2025年第二季度人工智能收入同比增长44%至44亿美元,半导体收入增长17%至149亿美元 [7] 华尔街评级 - 华尔街大多看好博通股票,24位专家共识将博通评为“强力买入”,12个月平均目标价252美元,上涨空间近50% [8]
If you invested $1k in Nvidia stock at the start of 2025, here's your return now
Finbold· 2025-03-31 19:23
文章核心观点 - 英伟达股票虽有积压订单增长和营收增长,但受市场回调影响股价下跌,不过从长期看仍是可靠投资,当前可观望等待更好入场点 [1][4][9] 英伟达股价表现 - 2024年10月英伟达股价首次突破140美元后进入区间震荡,2025年1月6日达到历史新高149.43美元 [1] - 1月底因DeepSeek成为竞争对手及美国关税实施,股价大幅下跌,3月28日收盘价109.67美元,年初以来跌幅18.33%,3月31日盘前交易低至105.82美元,年初至今跌幅达21.20% [2][3] - 年初投资1000美元英伟达股票,目前价值约788美元,绝对损失212美元,2025年英伟达表现逊于大盘,同期标准普尔500指数下跌4.90% [3][4] 英伟达仍具投资价值原因 - 股价回调并非公司核心业务疲软所致,市场对英伟达的看法未改变,分析师对其仍持乐观态度,12个月平均目标价暗示有较大上涨空间 [5] - 与2月相比,华尔街研究人员对英伟达的研究覆盖变化不大,表明其看好英伟达的观点未变 [7] - 虽内部人员抛售有所增加,但与其他人工智能企业相比,关键人员抛售的英伟达股票数量相对较少 [8] 投资建议 - 宏观趋势主导近期股价走势,英伟达股价可能跌破100美元,当前市盈率为26.61,可等待进一步下跌以获得更有吸引力的入场点 [9]
2 healthcare safe bets to buy ahead of Trump's pharmaceutical tariffs
Finbold· 2025-03-30 05:29
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty. Notably, the market is already on the downside, as Trump recently announced an additional 25% tariff on auto imports. It remains to be seen how a similar move in pharmaceuticals will evolve. Although the initial reaction to tariffs has led to ...
2 healthcare stocks to buy ahead of Trump's pharmaceutical tariffs
Finbold· 2025-03-30 05:29
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty. Notably, the market is already on the downside, as Trump recently announced an additional 25% tariff on auto imports. It remains to be seen how a similar move in pharmaceuticals will evolve. Although the initial reaction to tariffs has led to ...
Michael Burry's top pick earns 20% upside revision from Wall Street
Finbold· 2025-03-29 21:56
文章核心观点 华尔街看好阿里巴巴,因其在人工智能领域的布局及良好基本面,预计其将占据更多市场份额 [1][10] 持仓情况 - 截至2024年第四季度,阿里巴巴占迈克尔·伯里旗下Scion资产管理公司投资组合的16.43%,是其持仓中的关键赢家 [1] 股价表现 - 近期阿里巴巴股价波动加剧,3月28日收盘报132.43美元,下跌2.36%,年初至今涨幅超55% [2] - 股票交易专家帕特里克·沃克称,股价在强劲反弹后正在盘整,但仍处于良好状态 [3] - 股价突破104.40美元和109.10美元关键水平后涨幅超20%,当前回调是在强劲上升趋势中的健康盘整 [5] 评级与目标价调整 - 瑞穗证券将阿里巴巴目标价从140美元上调至170美元,涨幅20%,维持“跑赢大盘”评级,列为亚洲互联网板块首选 [5] - 3月13日,花旗维持买入评级,目标价170美元 [10] - 2月26日,基准重申“买入”评级,目标价190美元 [10] - 2月24日,伯恩斯坦将评级上调至“跑赢大盘”,目标价升至165美元 [11] 上调原因 - 瑞穗分析师詹姆斯·李强调,阿里巴巴在人工智能领域的布局是上调评级的关键驱动因素,本月早些时候宣布新AI模型QwQ - 32B后有稳定资金流入,该模型表现不逊于DeepSeek顶级模型R - 1 [6] - 阿里巴巴在扩展AI模型至通用人工智能、加速客户应用部署平台及提供跨行业终端用户解决方案方面的基础,是股价上涨的关键催化剂 [7] - 分析师对阿里巴巴非核心业务表示乐观,预计淘宝和天猫集团以外业务(占EBITDA的11%)亏损将在两年内实现盈亏平衡 [8] - 瑞穗将2026财年云业务收入增长预测从13%上调至17%,因产品路线图更强及中国企业IT支出情绪改善 [9] - 目标价上调至170美元反映出基于中国科技行业倍数扩张和宏观经济状况改善,对2026财年EBITDA估值从10倍提升至12倍 [9] 基本面情况 - 随着中国经济复苏,零售销售连续两年同比增长,阿里巴巴核心电商业务可能实现两位数增长 [12] - 管理层调整和业务分拆计划逆转后,公司战略稳固,投资者信心恢复,同时中国政府对科技行业态度更积极 [13]
1 no-brainer biotech giant to buy in April
Finbold· 2025-03-29 00:51
文章核心观点 - 减肥药物的出现使诺和诺德和礼来等生物科技巨头受益 2025 年以来二者股价走势分化 有理由认为诺和诺德股票是更好选择 [1][2] 股价表现 - 截至目前 礼来股票(NYSE: LLY)年初至今上涨 6.97% 诺和诺德股票(NYSE: NVO)同期下跌 18.87% [1] 股价分化原因 - 礼来拥有更强大的产品管线 其新产品在试验中表现更优 但市场规模巨大 这是否足以解释股价差异存疑 [2] 估值情况 - 礼来股票远期市盈率为 36.26 接近整体股市平均水平 诺和诺德股票远期市盈率仅 17.23 二者滚动市盈率分别为 69.29 和 21.45 [4] - 诺和诺德目前市销率处于 2020 年 3 月以来最低水平 [5][10] 华尔街观点 - 美国银行分析师担心诺和诺德一季度销售不及预期 预计全年销售和指引下调 2% 全年销售增速在 14% - 22% 但认为即便如此 诺和诺德仍是礼来的有效替代选择 目标价从 155 美元降至 131 美元 仍有 87/70% 的上涨空间 [6][7] - 整体上分析师对诺和诺德持谨慎乐观态度 10 位追踪该股票的分析师中 5 位认为是“买入” 5 位认为是“持有” 平均目标价 110.36 美元 较当前价格有 58.13% 的涨幅 [8] - 截至撰写时 礼来股票 12 个月平均目标价暗示有 25.04% 的涨幅 [11]